Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly

Clinical Endocrinology

Volumn 70, Issue 1, 2009, Pages 88-95

  Boero, L ^a   Manavela, M ^b   Gomez Rosso L ^a   Insua, C ^c   Berardi, V ^d   Fornari, M C ^d   Brites, F ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^c HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^d Bioalpha Laboratory   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALPHA4 INTEGRIN; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD18 ANTIGEN; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIN 1; GLUCOSE; GROWTH HORMONE; HORMONE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LIPOPROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ACROMEGALY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACROMEGALY; ADULT; AGED; ANTIGENS, CD18; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; ENDOTHELIN-1; FEMALE; HUMANS; INTEGRIN ALPHA4; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS; MALE; MIDDLE AGED; TRIGLYCERIDES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 58149162992     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03323.x     Document Type: Article

References (42)

1. Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J. Ibbertson, H.K. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95 102.
2. Cannavo, S., Almoto, B., Cavalli, G., Squadrito, S., Romanello, G., Vigo, M.T., Fiumara, F., Benvenga, S. Trimarchi, F. (2006) Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. Journal of Clinical Endocrinology and Metabolism, 91, 3766 3772.
3. Melmed, S., Casanueva, F., Cavagnini, F., Chanson, P., Frohman, L.A., Gaillard, R., Ghigo, E., Ho, K., Jaquet, P., Kleinberg, D., Lamberts, S., Laws, E., Lombardi, G., Sheppard, M.C., Thorner, M., Vance, M.L., Wass, J.A. Giustina, A. (2005) Consensus statement: medical management of acromegaly. European Journal of Endocrinology, 153, 737 740.
4. Colao, A., Marzullo, P., Di Somma, C. Lombardi, G. (2001) Growth hormone and the heart. Clinical Endocrinology, 54, 137 154.
5. Colao, A., Baldelli, R., Marzullo, P., Ferretti, E., Ferone, D., Gargiulo, P., Petretta, M., Tamburrano, G., Lombardi, G. Liuzzi, A. (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. Journal of Clinical Endocrinology and Metabolism, 85, 193 199.
6. Twickler, T.B., Dallinga-Thie, G.M., Zelissen, P.M., Koppeschaar, H.P. Erkelens, D.W. (2001) The atherogenic plasma remnant-like particle cholesterol concentration is increased in the fasting and postprandial state in active acromegalic patients. Clinical Endocrinology, 55, 69 75.
7. Tan, K.C., Shiu, S.W., Janus, E.D. Lam, K.S. (1997) LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I. Atherosclerosis, 129, 59 65.
8. Takeda, R., Tatami, R., Ueda, K., Sagara, H., Nakabayashi, H. Mabuchi, H. (1982) The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients. Acta Endocrinologica (Copenh), 100, 358 362.
9. Beentjes, J.A., van Tol, A., Sluiter, W.J. Dullaart, R.P. (2000) Low plasma lecithin: cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis, 153, 491 498.
10. Hainer, V., Zak, A., Sindelkova, E., Wernischova, V., Belikovova, H. Skorepa, J. (1985) Elevation of high density lipoproteins in acromegalics after lisuride treatment. LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate Metabolism Research, 17, 220 221.
11. Arosio, M., Sartore, G., Rossi, C.M., Casati, G., Faglia, G. Manzato, E. (2000) LDL physical properties, lipoprotein and Lp (a) levels in acromegalic patients. Effects of octreotide therapy. Italian multicenter octreotide study group. Atherosclerosis, 151, 551 557.
12. Maffei, P., Sicolo, N. Plebani, M. (1999) Lipoprotein (a) in acromegaly. Annals of Internal Medicine, 130, 537 538.
13. Colao, A., Spiezia, S., Cerbone, G., Pivonello, R., Marzullo, P., Ferone, D., Di Somma, C., Assanti, A.P. Lombardi, G. (2001) Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clinical Endocrinology, 54, 515 524.
14. Sesmilo, G., Fairfield, W.P., Katznelson, L., Pulaski, K., Freda, P.U., Bonert, V., Dimaraki, E., Stavrou, S., Vance, M.L., Hayden, D. Klibanski, A. (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. Journal of Clinical Endocrinology and Metabolism, 87, 1692 1699.
15. Giustina, A., Barkan, A., Casanueva, F.F., Cavagnini, F., Frohman, L., Ho, K., Veldhuis, J., Wass, J., Von Werder, K. Melmed, S. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526 529.
16. Assmann, G., Jabs, H.U., Kohnert, U., Nolte, W. Schriewer, H. (1984) LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate. Clinical Chimica Acta, 140, 77 83.
17. 2+ precipitation procedure for quantitation of high-density- lipoprotein cholesterol. Clinical Chemistry, 28, 1379 1388.
18. Lagrost, L., Gandjini, H., Athias, A., Guyard-Dangremont, V., Lallemant, C. Gambert, P. (1993) Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 13, 815 825.
19. Blank, M.L., Hall, M.N., Cress, E.A. Snyder, F. (1983) Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats. Biochemistry and Biophysics Research Communications, 113, 666 671.
20. Fornari, M.C., Sarto, A., Berardi, V.E., Martinez, M.A., Rocha, M.G., Pasqualini, S. Diez, R.A. (2002) Effect of ovaric hyper-stimulation on blood lymphocyte subpopulations, cytokines, leptin and nitrite among patients with unexplained infertility. American Journal of Reproduction Immunology, 48, 394 403.
21. McLaughlin, T., Abbasi, F., Cheal, K., Chu, J., Lamendola, C. Reaven, G. (2003) Use of metabolic markers to identify overweight individuals who are insulin resistant. Annals of Internal Medicine, 139, 802 809.
22. Luger, A., Prager, R., Gaube, S., Graf, H., Klauser, R. Schernthaner, G. (1990) Decreased peripheral insulin sensitivity in acromegalic patients. Experimental Clinical Endocrinology, 95, 339 343.
23. Bolinder, J., Ostman, J., Werner, S. Arner, P. (1986) Insulin action in human adipose tissue in acromegaly. Journal of Clinical Investigations, 77, 1201 1206.
24. Clemmons, D.R. (2002) Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary, 5, 181 183.
25. Taskinen, M.R. (1995) Insulin resistance and lipoprotein metabolism. Current Opinions in Lipidology, 6, 153 160.
26. Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J. Lisheng, L. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 364, 937 952.
27. McLaughlin, T., Reaven, G., Abbasi, F., Lamendola, C., Saad, M., Waters, D., Simon, J. Krauss, R.M. (2005) Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? American Journal of Cardiology, 96, 399 404.
28. Ottosson, M., Vikman-Adolfsson, K., Enerback, S., Elander, A., Bjorntorp, P. Eden, S. (1995) Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. Journal of Clinical Endocrinology and Metabolism, 80, 936 941.
29. Ottosson, M., Lonnroth, P., Bjorntorp, P. Eden, S. (2000) Effects of cortisol and growth hormone on lipolysis in human adipose tissue. Journal of Clinical Endocrinology and Metabolism, 85, 799 803.
30. Saccà, L., Napoli, R. Cittadini, A. (2003) Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clinical Endocrinology, 59, 660 671.
31. Miller, R.C., Pelton, J.T. Huggins, J.P. (1993) Endothelins - from receptors to medicine. Trends in Pharmacological Science, 14, 54 60.
32. Sainani, G.S., Maru, V.G. Mehra, A.P. (2005) Role of endothelin-1 in genesis of coronary artery disease. Indian Heart Journal, 57, 121 127.
33. Longobardi, S., Di Somma, C., Di Rella, F., Angelillo, N., Ferone, D., Colao, A., Merola, B. Lombardi, G. (1998) Bone mineral density and circulating cytokines in patients with acromegaly. Journal of Endocrinological Investigation, 21, 688 693.
34. Messai, H., Khatib, A.M., Lebrun, G., Aubin, P., Florina, M., Jean, F. Mitrovic, D.R. (2000) Endothelin-1 in monolayer cultures of articular chondrocytes from young and old rats: regulation by growth factors and cytokines. Mechanisms of Ageing and Development, 114, 37 48.
35. Yang, L.L., Arab, S., Liu, P., Stewart, D.J. Husain, M. (2005) The role of endothelin-1 in myocarditis and inflammatory cardiomyopathy: old lessons and new insights. Canadian Journal of Physiological Pharmacology, 83, 47 62.
36. Huo, Y. Ley, K. (2001) Adhesion molecules and atherogenesis. Acta Physiologica Scandinavica, 173, 35 43.
37. Li, L., Chu, Y., Fink, G.D., Engelhardt, J.F., Heistad, D.D. Chen, A.F. (2003) Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. Hypertension, 42, 997 1003.
38. Fan, J. Watanabe, T. (2003) Inflammatory reactions in the pathogenesis of atherosclerosis. Journal of Atherosclerosis and Thrombosis, 10, 63 71.
39. Jakab, L. Kalabay, L. (1998) The acute phase reaction syndrome: the acute phase reactants. Acta Microbiologica Immunologica Hungarica, 45, 409 418.
40. Derfalvi, B., Igaz, P., Fulop, K.A., Szalai, C. Falus, A. (2000) Interleukin-6-induced production of type II acute phase proteins and expression of junB gene are downregulated by human recombinant growth hormone in vitro. Cell Biology International, 24, 109 114.
41. Tsimikas, S., Willerson, J.T. Ridker, P.M. (2006) C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. Journal of the American College of Cardiology, 47 (8 Suppl C19 C31.
42. Núñez, J., Núñez, E., Sanchis, J., Bodí, V. Llàcer, A. (2006) Prognostic value of leukocytosis in acute coronary syndromes: the cinderella of the inflammatory markers. Current Medical Chemistry, 13, 2113 2118.